Evidence map›Paper›PMID 31019982›Full record

ArticleJournal of immunology research2019

Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.

Karim Dorgham, Nicolas Pietrancosta, Amel Affoune, Olivier Lucar, Tahar Bouceba, Solenne Chardonnet, Cedric Pionneau, Christophe Piesse, Delphine Sterlin, Pablo Guardado-Calvo and 4 more

Abstract read
In one paragraph

Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karim DorghamSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.ORCID 0000-0001-9539-3203
Nicolas PietrancostaUniversité Sorbonne Paris Cité, CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, F-75006 Paris, France.
Amel AffouneSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.
Olivier LucarSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.
Tahar BoucebaSorbonne Université, CNRS, Institut de Biologie Paris-Seine (IBPS), Service de Synthèse Peptidique et d'Interactions Moléculaires, F-75005 Paris, France.
Solenne ChardonnetSorbonne Université, INSERM, Plateforme Post-génomique de la Pitié Salpêtrière (P3S), F-75013 Paris, France.
Cedric PionneauSorbonne Université, INSERM, Plateforme Post-génomique de la Pitié Salpêtrière (P3S), F-75013 Paris, France.
Christophe PiesseSorbonne Université, CNRS, Institut de Biologie Paris-Seine (IBPS), Service de Synthèse Peptidique et d'Interactions Moléculaires, F-75005 Paris, France.
Delphine SterlinSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.
Pablo Guardado-CalvoInstitut Pasteur, Unité de Virologie Structurale (VIST), F-75015 Paris, France.
Philippe KaroyanSorbonne Université, Ecole Normale Supérieure, PSL University, CNRS, Laboratoire des Biomolécules, LBM, F-75005 Paris, France.
Patrice DebréSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.
Guy GorochovSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.
Vincent VieillardSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), F-75013 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The design of immunogens susceptible to elicit potent and broadly neutralizing antibodies against the human immunodeficiency virus type 1 (HIV-1) remains a veritable challenge in the course of vaccine development. Viral envelope proteins adopt different conformational states during the entry process, allowing the presentation of transient neutralizing epitopes. We focused on the highly conserved 3S motif of gp41, which is exposed to the surface envelope in its trimeric prefusion state. Vaccination with a W614A-modified 3S peptide induces in animals neutralizing anti-HIV-1 antibodies among which we selected clone F8. We used F8 as bait to select for W614A-3S phage-peptide mimics. Binding and molecular docking studies revealed that F8 interacts similarly with W614A-3S and a Mim_F8-1 mimotope, despite their lack of sequence homology, suggesting structural mimicry. Finally, vaccination of mice with the purified Mim_F8-1 phage elicited HIV-1-neutralizing antibodies that bound to the cognate W614A-3S motif. Collectively, our findings provide new insights into the molecular design of immunogens to elicit antibodies with neutralizing properties.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBacteriophagesEpitope MappingEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp41MiceMice, Inbred BALB CModels, MolecularMolecular Docking SimulationNeutralization TestsPeptidesProtein BindingAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp41Peptides

Identifiers

PMID31019982
PMCPMC6451809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.